Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Life-threatening acute myocardial infarction due to left main dissection during radiofrequency transcatheter ablation of atrial tachycardia.

Cafaro A, Cecere A, Ruggieri R, Iorio E, Giardinelli F, Ciccone MM, Casamassima V, Grimaldi M, Langialonga T, Pepe M.

Cardiol J. 2019;26(2):196-197. doi: 10.5603/CJ.2019.0041. No abstract available.

2.

Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.

Sgadari C, Monini P, Tripiciano A, Picconi O, Casabianca A, Orlandi C, Moretti S, Francavilla V, Arancio A, Paniccia G, Campagna M, Bellino S, Meschiari M, Nozza S, Sighinolfi L, Latini A, Muscatello A, Saracino A, Di Pietro M, Galli M, Cafaro A, Magnani M, Ensoli F, Ensoli B.

Front Immunol. 2019 Feb 13;10:233. doi: 10.3389/fimmu.2019.00233. eCollection 2019.

3.

Treatment Outcome of Oral Leukoplakia with Er:YAG Laser: A 5-Year Follow-Up Prospective Comparative Study.

Arduino PG, Cafaro A, Cabras M, Gambino A, Broccoletti R.

Photomed Laser Surg. 2018 Oct 19. doi: 10.1089/pho.2018.4491. [Epub ahead of print]

PMID:
30339489
4.

Time-dependent benefits of pre-treatment with new oral P2Y12 -inhibitors in patients addressed to primary PCI for acute ST-elevation myocardial infarction.

Pepe M, Cafaro A, Paradies V, Signore N, Addabbo F, Bortone AS, Navarese EP, Contegiacomo G, Forleo C, Bartolomucci F, Di Cillo O, Bianchi FP, Zanna D, Favale S.

Catheter Cardiovasc Interv. 2019 Mar 1;93(4):592-601. doi: 10.1002/ccd.27863. Epub 2018 Sep 30.

PMID:
30269413
5.

Fractional flow reserve and intravascular scan as part of the coronary fistulas diagnostic process: Future perspectives.

Pepe M, Giardinelli F, Cafaro A, Masi F, Navarese EP, Tito A, Resta F, Cecere A, Ciccone MM, Favale S.

Cardiol J. 2018;25(3):414-415. doi: 10.5603/CJ.2018.0059. No abstract available.

6.

Role of plasma glucose level on myocardial perfusion in ST-segment elevation myocardial infarction patients.

Pepe M, Zanna D, Cafaro A, Marchese A, Addabbo F, Navarese EP, Napodano M, Cecere A, Resta F, Paradies V, Bortone AS, Favale S.

J Diabetes Complications. 2018 Aug;32(8):764-769. doi: 10.1016/j.jdiacomp.2018.05.015. Epub 2018 May 26.

PMID:
29937139
7.

The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naïve CD4+ T cells.

Nicoli F, Gallerani E, Sforza F, Finessi V, Chachage M, Geldmacher C, Cafaro A, Ensoli B, Caputo A, Gavioli R.

AIDS. 2018 Mar 13;32(5):575-581. doi: 10.1097/QAD.0000000000001734.

PMID:
29280760
8.

"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies".

Cafaro A, Sgadari C, Picconi O, Tripiciano A, Moretti S, Francavilla V, Pavone Cossut MR, Buttò S, Cozzone G, Ensoli F, Monini P, Ensoli B.

Expert Rev Vaccines. 2018 Feb;17(2):115-126. doi: 10.1080/14760584.2018.1418666. Epub 2017 Dec 22. Review.

PMID:
29243498
9.

Laser Photobiomodulation for a Complex Patient with Severe Hydroxyurea-Induced Oral Ulcerations.

Cabras M, Cafaro A, Gambino A, Broccoletti R, Romagnoli E, Marina D, Arduino PG.

Case Rep Dent. 2016;2016:9810480. Epub 2016 Nov 10.

10.

Impact of a sodium carbonate spray combined with professional oral hygiene procedures in patients with Sjögren's syndrome: an explorative study.

Gambino A, Broccoletti R, Cafaro A, Cabras M, Carcieri P, Arduino PG.

Gerodontology. 2017 Jun;34(2):208-214. doi: 10.1111/ger.12250. Epub 2016 Nov 4.

PMID:
27813150
11.

HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.

Cafaro A, Piccaro G, Altavilla G, Gigantino V, Matarese G, Olivieri E, Ferrantelli F, Ensoli B, Palma C.

BMC Infect Dis. 2016 Aug 22;16(1):442. doi: 10.1186/s12879-016-1724-7.

12.

Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.

Nicoli F, Chachage M, Clowes P, Bauer A, Kowour D, Ensoli B, Cafaro A, Maboko L, Hoelscher M, Gavioli R, Saathoff E, Geldmacher C.

BMC Infect Dis. 2016 Jul 22;16:344. doi: 10.1186/s12879-016-1647-3.

13.

HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.

Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, Bellino S, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, Cafaro A, Francavilla V, Moretti S, Pavone Cossut MR, Collacchi B, Arancio A, Paniccia G, Casabianca A, Magnani M, Buttò S, Levendal E, Ndimande JV, Asia B, Pillay Y, Garaci E, Monini P; SMU-MeCRU study group.

Retrovirology. 2016 Jun 9;13(1):34. doi: 10.1186/s12977-016-0261-1.

14.

'Broken-heart' syndrome: ventricular septal perforation in a takotsubo cardiomyopathy.

Pepe M, Paradies V, Bortone A, De Cillis E, Cafaro A, Acquaviva T, Masi F, Quagliara D, Favale S.

Future Cardiol. 2016 May;12(3):255-9. doi: 10.2217/fca.16.4. Epub 2016 Apr 19.

PMID:
27091371
15.

Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection.

Nicoli F, Gallerani E, Skarlis C, Sicurella M, Cafaro A, Ensoli B, Caputo A, Marconi PC, Gavioli R.

Vaccine. 2016 Apr 27;34(19):2216-24. doi: 10.1016/j.vaccine.2016.03.022. Epub 2016 Mar 19.

PMID:
27002499
16.

A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome.

Arduino PG, Cafaro A, Garrone M, Gambino A, Cabras M, Romagnoli E, Broccoletti R.

Lasers Med Sci. 2016 May;31(4):811-6. doi: 10.1007/s10103-016-1897-8. Epub 2016 Feb 12.

PMID:
26873501
17.

Er:YAG Laser Versus Cold Knife Excision in the Treatment of Nondysplastic Oral Lesions: A Randomized Comparative Study for the Postoperative Period.

Broccoletti R, Cafaro A, Gambino A, Romagnoli E, Arduino PG.

Photomed Laser Surg. 2015 Dec;33(12):604-9. doi: 10.1089/pho.2015.3967. Epub 2015 Nov 20.

PMID:
26588688
18.

Emergency coronary and peripheral arteries combined with percutaneous intervention in the elderly: success or therapeutic excess?

Pepe M, Furgieri A, Miranda M, Cafaro A, Paradies V, Iacovelli F, Castriota F, Liso A.

Future Cardiol. 2015 Sep;11(5):521-4. doi: 10.2217/fca.15.52. Epub 2015 Sep 25.

PMID:
26403439
19.

Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.

Cafaro A, Tripiciano A, Sgadari C, Bellino S, Picconi O, Longo O, Francavilla V, Buttò S, Titti F, Monini P, Ensoli F, Ensoli B.

Expert Opin Biol Ther. 2015;15 Suppl 1:S13-29. doi: 10.1517/14712598.2015.1021328. Epub 2015 Jun 22. Review.

PMID:
26096836
20.

HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.

Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B.

Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.

21.

Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide.

Finessi V, Nicoli F, Gallerani E, Sforza F, Sicurella M, Cafaro A, Caputo A, Ensoli B, Gavioli R.

Hum Vaccin Immunother. 2015;11(6):1489-93. doi: 10.1080/21645515.2015.1016676.

22.

Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines.

Titti F, Maggiorella MT, Ferrantelli F, Sernicola L, Bellino S, Collacchi B, Fanales Belasio E, Moretti S, Pavone Cossut MR, Belli R, Olivieri E, Farcomeni S, Compagnoni D, Michelini Z, Sabbatucci M, Sparnacci K, Tondelli L, Laus M, Cafaro A, Caputo A, Ensoli B.

PLoS One. 2014 Oct 30;9(10):e111360. doi: 10.1371/journal.pone.0111360. eCollection 2014.

23.

Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner.

Chiozzini C, Collacchi B, Nappi F, Bauer T, Arenaccio C, Tripiciano A, Longo O, Ensoli F, Cafaro A, Ensoli B, Federico M.

AIDS. 2014 Sep 24;28(15):2189-200. doi: 10.1097/QAD.0000000000000389.

PMID:
25313583
24.

Challenges in HIV Vaccine Research for Treatment and Prevention.

Ensoli B, Cafaro A, Monini P, Marcotullio S, Ensoli F.

Front Immunol. 2014 Sep 8;5:417. doi: 10.3389/fimmu.2014.00417. eCollection 2014. Review.

25.

An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge.

Sicurella M, Nicoli F, Gallerani E, Volpi I, Berto E, Finessi V, Destro F, Manservigi R, Cafaro A, Ensoli B, Caputo A, Gavioli R, Marconi PC.

PLoS One. 2014 Jul 17;9(7):e100844. doi: 10.1371/journal.pone.0100844. eCollection 2014.

26.

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.

Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B.

Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.

27.

Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice.

Garulli B, Di Mario G, Stillitano MG, Compagnoni D, Titti F, Cafaro A, Ensoli B, Kawaoka Y, Castrucci MR.

Biomed Res Int. 2014;2014:904038. doi: 10.1155/2014/904038. Epub 2014 May 14.

28.

HIV-1 Tat affects the programming and functionality of human CD8⁺ T cells by modulating the expression of T-box transcription factors.

Sforza F, Nicoli F, Gallerani E, Finessi V, Reali E, Cafaro A, Caputo A, Ensoli B, Gavioli R.

AIDS. 2014 Jul 31;28(12):1729-38. doi: 10.1097/QAD.0000000000000315.

PMID:
24841128
29.

Effect of laser acupuncture on salivary flow rate in patients with Sjögren's syndrome.

Cafaro A, Arduino PG, Gambino A, Romagnoli E, Broccoletti R.

Lasers Med Sci. 2015 Aug;30(6):1805-9. doi: 10.1007/s10103-014-1590-8. Epub 2014 May 13.

PMID:
24820476
30.

Effect of MHC haplotype on immune response upon experimental SHIVSF162P4cy infection of Mauritian cynomolgus macaques.

Borsetti A, Ferrantelli F, Maggiorella MT, Sernicola L, Bellino S, Gallinaro A, Farcomeni S, Mee ET, Rose NJ, Cafaro A, Titti F, Ensoli B.

PLoS One. 2014 Apr 2;9(4):e93235. doi: 10.1371/journal.pone.0093235. eCollection 2014.

31.

LLLT in combination with non-surgical periodontal therapy in patients with gingival oral lichen planus: a pilot study.

Gambino A, Cafaro A, Arduino PG, Conrotto D, Broccoletti R.

Ann Stomatol (Roma). 2013 Oct 24;4(Suppl 2):19. eCollection 2013. No abstract available.

32.

Low level laser therapy (LLLT) as adjuvant in the management of drug induced gingival hyperplasia: a case report.

Cafaro A, Arduino PG, Broccoletti R, Romagnoli E.

Ann Stomatol (Roma). 2013 Oct 24;4(Suppl 2):8-9. eCollection 2013. No abstract available.

33.

The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses.

Nicoli F, Finessi V, Sicurella M, Rizzotto L, Gallerani E, Destro F, Cafaro A, Marconi P, Caputo A, Ensoli B, Gavioli R.

PLoS One. 2013 Nov 4;8(11):e77746. doi: 10.1371/journal.pone.0077746. eCollection 2013.

34.

Clinical evaluation of the efficiency of low-level laser therapy for oral lichen planus: a prospective case series.

Cafaro A, Arduino PG, Massolini G, Romagnoli E, Broccoletti R.

Lasers Med Sci. 2014 Jan;29(1):185-90. doi: 10.1007/s10103-013-1313-6. Epub 2013 Apr 3.

35.

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.

Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B.

PLoS One. 2012;7(11):e48781. doi: 10.1371/journal.pone.0048781. Epub 2012 Nov 13.

36.

Low-level laser therapy for oral mucous membrane pemphigoid.

Cafaro A, Broccoletti R, Arduino PG.

Lasers Med Sci. 2012 Nov;27(6):1247-50. doi: 10.1007/s10103-012-1137-9. Epub 2012 Jun 16. No abstract available.

PMID:
22706567
37.

Influence of MHC class I and II haplotypes on the experimental infection of Mauritian cynomolgus macaques with SHIVSF162P4cy.

Borsetti A, Maggiorella MT, Sernicola L, Bellino S, Ferrantelli F, Belli R, Fulgenzi D, Mee ET, Rose NJ, Cafaro A, Ensoli B, Titti F.

Tissue Antigens. 2012 Jul;80(1):36-45. doi: 10.1111/j.1399-0039.2012.01875.x. Epub 2012 Apr 12.

PMID:
22494179
38.

Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules.

Fraternale A, Paoletti MF, Dominici S, Buondelmonte C, Caputo A, Castaldello A, Tripiciano A, Cafaro A, Palamara AT, Sgarbanti R, Garaci E, Ensoli B, Magnani M.

Vaccine. 2011 Sep 16;29(40):6823-9. doi: 10.1016/j.vaccine.2011.07.101. Epub 2011 Aug 2.

PMID:
21816192
39.

A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.

Ferrantelli F, Maggiorella MT, Schiavoni I, Sernicola L, Olivieri E, Farcomeni S, Pavone-Cossut MR, Moretti S, Belli R, Collacchi B, Srivastava IK, Titti F, Cafaro A, Barnett SW, Ensoli B.

Vaccine. 2011 Apr 5;29(16):2918-32. doi: 10.1016/j.vaccine.2011.02.006. Epub 2011 Feb 21.

PMID:
21338681
40.

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E.

PLoS One. 2010 Nov 11;5(11):e13540. doi: 10.1371/journal.pone.0013540.

41.

Effect of low-level laser irradiation on unresponsive oral lichen planus: early preliminary results in 13 patients.

Cafaro A, Albanese G, Arduino PG, Mario C, Massolini G, Mozzati M, Broccoletti R.

Photomed Laser Surg. 2010 Oct;28 Suppl 2:S99-103. doi: 10.1089/pho.2009.2655. Epub 2010 Aug 25.

PMID:
20738169
42.

Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.

Cafaro A, Bellino S, Titti F, Maggiorella MT, Sernicola L, Wiseman RW, Venzon D, Karl JA, O'Connor D, Monini P, Robert-Guroff M, Ensoli B.

J Virol. 2010 Sep;84(17):8953-8. doi: 10.1128/JVI.00377-10. Epub 2010 Jun 16.

43.

Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS.

Cafaro A, Macchia I, Maggiorella MT, Titti F, Ensoli B.

Adv Exp Med Biol. 2009;655:189-242. doi: 10.1007/978-1-4419-1132-2_14. Review.

PMID:
20047043
44.

HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.

Caputo A, Gavioli R, Bellino S, Longo O, Tripiciano A, Francavilla V, Sgadari C, Paniccia G, Titti F, Cafaro A, Ferrantelli F, Monini P, Ensoli F, Ensoli B.

Int Rev Immunol. 2009;28(5):285-334. doi: 10.1080/08830180903013026. Review.

PMID:
19811313
45.

Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).

Borsetti A, Baroncelli S, Maggiorella MT, Moretti S, Fanales-Belasio E, Sernicola L, Tripiciano A, Macchia I, Michelini Z, Belli R, Farcomeni S, Pavone-Cossut MR, Negri D, Caputo A, Bellino S, Butto S, Titti F, Cafaro A, Ensoli B.

Viral Immunol. 2009 Apr;22(2):117-24. doi: 10.1089/vim.2008.0082.

PMID:
19326998
46.

Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, Summers LE, Venzon D, Cafaro A, Ensoli B, Robert-Guroff M.

J Immunol. 2009 Mar 15;182(6):3718-27. doi: 10.4049/jimmunol.0803115.

47.

HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.

Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone Cossut MR, Scoglio A, Collacchi B, Nappi F, Macchia I, Bellino S, Francavilla V, Caputo A, Barillari G, Magnani M, Laguardia ME, Cafaro A, Titti F, Monini P, Ensoli F, Ensoli B.

J Immunol. 2009 Mar 1;182(5):2888-97. doi: 10.4049/jimmunol.0711406.

48.

NKp44 expression, phylogenesis and function in non-human primate NK cells.

De Maria A, Ugolotti E, Rutjens E, Mazza S, Radic L, Faravelli A, Koopman G, Di Marco E, Costa P, Ensoli B, Cafaro A, Mingari MC, Moretta L, Heeney J, Biassoni R.

Int Immunol. 2009 Mar;21(3):245-55. doi: 10.1093/intimm/dxn144. Epub 2009 Jan 15.

49.

Anatomic lung resection for nontuberculous mycobacterial disease.

Mitchell JD, Bishop A, Cafaro A, Weyant MJ, Pomerantz M.

Ann Thorac Surg. 2008 Jun;85(6):1887-92; discussion 1892-3. doi: 10.1016/j.athoracsur.2008.02.041.

PMID:
18498789
50.

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.

Florese RH, Wiseman RW, Venzon D, Karl JA, Demberg T, Larsen K, Flanary L, Kalyanaraman VS, Pal R, Titti F, Patterson LJ, Heath MJ, O'Connor DH, Cafaro A, Ensoli B, Robert-Guroff M.

Vaccine. 2008 Jun 19;26(26):3312-21. doi: 10.1016/j.vaccine.2008.03.100. Epub 2008 Apr 30.

Supplemental Content

Loading ...
Support Center